ArticleNature communications2025

Rational development of gemcitabine-based nanoplatform for targeting SERPINB9/Granzyme B axis to overcome chemo-immune-resistance.

Haozhe Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.